AU2444899A - Pharmaceutical formulation comprising an antibody and a citrate buffer - Google Patents

Pharmaceutical formulation comprising an antibody and a citrate buffer

Info

Publication number: AU2444899A
Authority: AU; Australia
Prior art keywords: antibody; pharmaceutical formulation; citrate buffer; citrate; buffer
Prior art date: 1998-01-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU24448/99A

Inventor

Ola Flink

Sven Petren

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

AstraZeneca AB

Original Assignee

AstraZeneca AB

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-22

Filing date

1999-01-15

Publication date

1999-08-09

1998-01-22 Priority claimed from SE9800170A external-priority patent/SE9800170D0/en

1998-03-09 Priority claimed from SE9800766A external-priority patent/SE9800766D0/en

1999-01-15 Application filed by AstraZeneca AB filed Critical AstraZeneca AB

1999-08-09 Publication of AU2444899A publication Critical patent/AU2444899A/en

Status Abandoned legal-status Critical Current

Links

239000007979 citrate buffer Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AU24448/99A 1998-01-22 1999-01-15 Pharmaceutical formulation comprising an antibody and a citrate buffer Abandoned AU2444899A (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
SE9800170		1998-01-22
SE9800170A SE9800170D0 (en)	1998-01-22	1998-01-22	formulation
SE9800766		1998-03-09
SE9800766A SE9800766D0 (en)	1998-03-09	1998-03-09	formulation
PCT/SE1999/000049 WO1999037329A1 (en)	1998-01-22	1999-01-15	Pharmaceutical formulation comprising an antibody and a citrate buffer

Publications (1)

Publication Number	Publication Date
AU2444899A true AU2444899A (en)	1999-08-09

Family

ID=26663196

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU24448/99A Abandoned AU2444899A (en)	1998-01-22	1999-01-15	Pharmaceutical formulation comprising an antibody and a citrate buffer

Country Status (3)

Country	Link
AR (1)	AR017973A1 (en)
AU (1)	AU2444899A (en)
WO (1)	WO1999037329A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3031917A1 (en)	1999-04-09	2016-06-15	Kyowa Hakko Kirin Co., Ltd.	Method for controlling the activity of immunologically functional molecule
EP1254666A4 (en) *	1999-12-28	2004-12-22	Chugai Pharmaceutical Co Ltd	Stable antibody compositions and injection preparations
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20040033228A1 (en)	2002-08-16	2004-02-19	Hans-Juergen Krause	Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en)	2002-10-24	2014-02-28	Abbvie Biotechnology Ltd	Low dose methods for treating disorders in which tnf? activity is detrimental
EP2204190A1 (en)	2003-07-15	2010-07-07	Chugai Seiyaku Kabushiki Kaisha	IgM production by transformed cells and methods for quantifying said IgM production
SI1698640T2 (en) *	2003-10-01	2019-08-30	Kyowa Hakko Kirin Co., Ltd.	Method of stabilizing antibody and stabilized solution-type antibody preparation
US7803914B2 (en)	2003-10-09	2010-09-28	Chugai Seiyaku Kabushiki Kaisha	Methods for stabilizing protein solutions
US20070212346A1 (en)	2003-10-09	2007-09-13	Tomoyuki Igawa	Highly Concentrated Stabilized Igm Solution
EP1712240B1 (en) *	2003-12-25	2015-09-09	Kyowa Hakko Kirin Co., Ltd.	Stable water-based medicinal preparation containing antibody
US7662384B2 (en) *	2004-03-24	2010-02-16	Facet Biotech Corporation	Use of anti-α5β1 antibodies to inhibit cancer cell proliferation
TW200621282A (en)	2004-08-13	2006-07-01	Wyeth Corp	Stabilizing formulations
SMP200800064B (en) *	2006-04-21	2009-11-06	Novartis Ag	Pharmaceutical compositions of anti-cd40 antagonist antibodies
US8883146B2 (en)	2007-11-30	2014-11-11	Abbvie Inc.	Protein formulations and methods of making same
WO2013103783A1 (en) *	2012-01-04	2013-07-11	Sanofi Us	Murine il-13 antibodies
US8883979B2 (en)	2012-08-31	2014-11-11	Bayer Healthcare Llc	Anti-prolactin receptor antibody formulations
EA029215B1 (en)	2012-09-07	2018-02-28	Кохерус Байосайенсис, Инк.	Stable aqueous formulations of adalimumab
US11229702B1 (en)	2015-10-28	2022-01-25	Coherus Biosciences, Inc.	High concentration formulations of adalimumab
US11071782B2 (en)	2016-04-20	2021-07-27	Coherus Biosciences, Inc.	Method of filling a container with no headspace

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0417191B1 (en) *	1988-05-27	1993-03-10	Centocor, Inc.	Formulation for antibody reagents
JPH04504253A (en) *	1989-03-27	1992-07-30	セントカー・インコーポレーテツド	Formulations for the stabilization of IgM antibodies
JPH0565233A (en) *	1991-03-08	1993-03-19	Mitsui Toatsu Chem Inc	Monoclonal antibody-containing lyophilized preparation
JP4157160B2 (en) *	1991-12-13	2008-09-24	ゾーマテクノロジーリミテッド	Methods for the preparation of modified antibody variable regions
GB9325182D0 (en) *	1993-12-08	1994-02-09	T Cell Sciences Inc	Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions

1999
- 1999-01-15 AU AU24448/99A patent/AU2444899A/en not_active Abandoned
- 1999-01-15 WO PCT/SE1999/000049 patent/WO1999037329A1/en active Application Filing
- 1999-01-21 AR ARP990100239A patent/AR017973A1/en unknown

Also Published As

Publication number	Publication date
AR017973A1 (en)	2001-10-24
WO1999037329A1 (en)	1999-07-29

Legal Events

Date	Code	Title	Description
2000-10-05	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
2001-04-26	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase

Publication	Publication Date	Title
AU2444899A (en)	1999-08-09	Pharmaceutical formulation comprising an antibody and a citrate buffer
AU5020400A (en)	2000-12-12	Heteroaryloxypyrimidine insecticides and acaricides
AU5440901A (en)	2001-07-03	Cosmetic and/or pharmaceutical preparations
AU2543399A (en)	1999-09-15	Anticonvulsant drugs and pharmaceutical compositions thereof
AU3117400A (en)	2000-08-18	Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
AU3472799A (en)	1999-10-25	Dermatological formulations and methods
AU6124999A (en)	2000-05-08	Hydrazinooxoacetamide derivatives and insecticide
AU6213699A (en)	2000-04-17	Nutritional and pharmaceutical compositions
AU2438400A (en)	2000-08-18	Cosmetic and/or pharmaceutical preparations
AU4777100A (en)	2000-11-10	Nutraceuticals and ingredients for functional foods
AU4293800A (en)	2000-11-14	Cosmetic and/or pharmaceutical preparations
AUPP672198A0 (en)	1998-11-19	Pyrazolopyridine compound and pharmaceutical use thereof
AU3357700A (en)	2000-09-04	Phenoxypyrimidine insecticides and acaricides
AU6179600A (en)	2001-04-10	Peptides and pharmaceutical compositions comprising same
AU2136401A (en)	2001-06-25	P450rai-2 and related proteins
AU1800100A (en)	2000-07-31	Medicinal preparations
AU7681498A (en)	1998-12-11	Pharmaceutical composition and use thereof
AU5416898A (en)	1998-06-29	Cisplatinum comprising pharmaceutical
AUPP363498A0 (en)	1998-06-11	Antigens and their detection
AU2880699A (en)	1999-10-25	Pharmaceutical compositions and methods for use
AU5182099A (en)	2000-03-06	Pharmaceutical formulation
AU2001253658A1 (en)	2001-10-30	A glycopeptide and preparation thereof
AU6396399A (en)	2001-04-24	Package and method
AU6520198A (en)	1998-10-22	Quinolinomorphinane derivatives and medicinal use thereof
AU4166399A (en)	2000-01-05	Packaged pesticide preparations